In summary, the current clinical trials related to targeted cancer metabolism encompass a diverse array of drugs and targets, including KRAS G12C, HER2, Trop-2, PD-1/PD-L1, TIGIT, and NTRK fusion genes. This evidence concerns the gene TIGIT and cancer.